Clinical trials: Glucagon
Type 1 Diabetes
Biomarkers of Heterogeneity in Type 1 Diabetes
Biomarkers of heterogeneity in type 1 diabetes: establishment of a biobank and an integrated approach to clinical and metabolic phenotyping of individuals with established T1DM.
- Trial name
- NCT04977635
- Where
- 3 sites in Netherlands
- Volunteers
- 611 people
- Sponsor
- Diabeter Nederland BV
Esophageal Neoplasms, Stomach Neoplasms
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
Improvements to treatment strategies for patients with cancers of the upper gastrointestinal tract have produced a large population of people who remain free from cancer recurrence in the long term following treatment.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02381249
- Testing
- Octreotide
- Where
- 2 sites in Ireland, Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure
People with type 2 diabetes experience heart failure more often than do people without diabetes. This may be due to increased stiffness in the heart as a result of diabetes.
- Trial name
- NCT00799435
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Baylor College of Medicine
Diabetes Mellitus, Type 2, Obesity
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Obesity and Insulin Resistance
Being overweight or obese has been associated with insulin resistance contributing to an increased risk for the development of type II diabetes.
- Trial name
- NCT04926415
- Testing
- taVNS
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Burrell College of Health Sciences
Liver Disease
Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography
Morphine can induce constriction of sphincter of oddi and glucagon can facilitate bile secretion and dilatation of bile duct. We conduct this randomized double blinded study to evaluate the effect of enhancement in MRCP using…
- Trial name
- NCT00155376
- Testing
- morphine and glucagon
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Type 2 Diabetes Mellitus
Evaluation of the Glucoregulatory Effects of Glucagon-like Peptide-1 Receptor (GLP-1 Receptor) Activation in Participants With Type 2 Diabetes Mellitus (MK-0000-222)
This was a four-period crossover study to assess the glycemic effects of a single dose of oxyntomodulin (OXM) on the glucose levels in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01373450
- Testing
- Oxyntomodulin, Liraglutide 0.6 mg, Liraglutide 1.2 mg
- Volunteers
- 12 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Obesity
Study of the Gut Hormone Analogue G3215 in Adult Subjects
A randomised, placebo controlled Phase I study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of G3215 in adult subjects.
- Trial name
- NCT02692040
- Testing
- G3215
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Cerebral Glucose Metabolism
The Effect of Glucagon on Cerebral Glucose Metabolism in Healthy Humans
This is a pilot study in which the investigators will investigate the effect of exogenous glucagon on cerebral glucose metabolism in healthy humans.
- Trial name
- GluCoMet_CD (NCT06877208)
- Testing
- Glucagon (part C), Glucose clamp (part C), Saline (part C)
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nicolai Jacob Wewer Albrechtsen
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Type 1 Diabetes
The Role of Amylin and Glucagon in T1DM
The purpose of this study is to see if giving pramlintide and insulin before a meal would lower high blood sugar and if a glucagon (a naturally made hormone in the body but reduced in diabetes and its role is in prevention of low…
- Trial name
- NCT00206258
- Testing
- Pramlintide and glucagon
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Severe Hypoglycemia, Type1diabetes
Longitudinal Study of the GLUcagon REsponse to Hypoglycemia in Children and Adolescents With New-onset Type 1 DIAbetes
The GLUREDIA study investigates the counter-regulatory response (CRR) during hypoglycemia in children with type 1 diabetes (T1D).
- Trial name
- GLUREDIA (NCT06770621)
- Testing
- Insulin-induced hypoglycemia test, Glucagon profile, Biological sample once
- Where
- Belgium
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Hypoglycemia
Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia
The purpose of this study is to determine whether glucagon administered by microneedle patch is comparable to glucagon administered by injection pen in the treatment of insulin-induced hypoglycemia.
- Trial name
- NCT02459938
- Testing
- Glucagon (ZP-Glucagon), Glucagon (GlucaGen)
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Zosano Pharma Corporation
Obesity, Type 2 Diabetes
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
The aim of this study is to investigate if endogenous Glucagon Like Peptide -1 (GLP-1) has an effect on brain satiety and reward systems and if there are alterations in obese patients with type 2 diabetes (T2DM).
- Trial name
- LIBRA (NCT01363609)
- Testing
- Liraglutide treatment 12 weeks, insulin glargine treatment, GLP-1 receptor antagonist
- Where
- Netherlands
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Hypoglycemia, Type1diabetes
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D).
- Trial name
- NCT05973799
- Testing
- Fasting, Feeding
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Cincinnati
Diabetes Mellitus, Type 1
Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection.
- Trial name
- NCT01997411
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Obesity With Diabetes, Overweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: Percent change in body weight Change in hemoglobin A1c (HbA1c)
- Trial name
- KaiNETIC-2 (NCT07284901)
- Testing
- Ribupatide
- Where
- 173 sites in United States, Argentina and 9 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Non-diabetec Obesity, Obesity (Disorder)
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
This randomized controlled trial evaluates the efficacy of three weekly GLP-1 receptor agonists (dulaglutide, semaglutide, and tirzepatide) in non-diabetic obese adults.
- Trial name
- NCT07834398
- Testing
- Dulaglutide, Semagludtide, Tirzepatide
- Where
- Saudi Arabia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Obesity (Disorder), GLP-1 Receptor Agonist Treatment
Probiotics in Obese Patients Treated With Semaglutide
This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide.
- Conditions
- Obesity (Disorder), GLP-1 Receptor Agonist Treatment, Probiotic Intervention, Diabetes Mellitus Type 2
- Trial name
- ProSem (NCT07847593)
- Testing
- Four-strain probiotic formulation
- Where
- 3 sites in Poland
- Volunteers
- 102 people
- Sponsor
- Nordic Biotic Sp. z o.o.
Diabetes Mellitus, Type 2
The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones
The aim of this study is to investigate the effects of combined administration of mosapride as modulator of gastrointestinal motility and DPP-4 inhibitor on secretion of gut hormone such as glucagon-like peptide-1 (GLP-1) and…
- Trial name
- NCT02180334
- Testing
- Mosapride citrate, Linagliptin, Acetaminophen (paracetamol)
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Metformin, Obesity, Abdominal
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
- Conditions
- Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2, Abdominal Fat
- Trial name
- NCT05779644
- Testing
- Liraglutide, Semaglutide, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital